LEADER 02180oam 2200613 450 001 9910707041103321 005 20160325114808.0 035 $a(CKB)5470000002461078 035 $a(OCoLC)891382290 035 $a(EXLCZ)995470000002461078 100 $a20140926d1965 ua 0 101 0 $aeng 135 $aurbn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Lexington limestone (Middle Ordovician) of central Kentucky /$fby Douglas F. B. Black, Earle R. Cressman, and William C. MacQuown, Jr. ; prepared in cooperation with the Kentucky Geological Survey 210 1$a[Washington, D.C.] :$cUnited States Department of the Interior, Geological Survey,$d1965. 210 2$aWashington :$cUnited States Government Printing Office. 215 $a1 online resource (iii, 29 pages) $cillustrations 225 1 $aGeological Survey bulletin ;$v1224-C 225 1 $aContributions to stratigraphy 300 $aTitle from title screen (viewed September 15, 2014). 320 $aIncludes bibliographical references (pages 28-29). 517 $aLexington limestone 606 $aGeology$zKentucky 606 $aGeology, Stratigraphic$yOrdovician 606 $aLimestone$zKentucky 606 $aGeology$2fast 606 $aGeology, Stratigraphic$2fast 606 $aLimestone$2fast 606 $aOrdovician Geologic Period$2fast 607 $aKentucky$2fast 615 0$aGeology 615 0$aGeology, Stratigraphic 615 0$aLimestone 615 7$aGeology. 615 7$aGeology, Stratigraphic. 615 7$aLimestone. 615 7$aOrdovician Geologic Period. 700 $aBlack$b Douglas F. B.$01392278 702 $aCressman$b Earle Rupert$f1923- 702 $aMacQuown$b William C.$cJr.$g(William Charles),$f1915-2007, 712 02$aGeological Survey (U.S.), 712 02$aKentucky Geological Survey, 801 0$bCOP 801 1$bCOP 801 2$bOCLCO 801 2$bOCLCF 801 2$bGPO 906 $aBOOK 912 $a9910707041103321 996 $aThe Lexington limestone (Middle Ordovician) of central Kentucky$93529515 997 $aUNINA LEADER 04847nam 2201717z- 450 001 9910557612103321 005 20220321 035 $a(CKB)5400000000045281 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79644 035 $a(oapen)doab79644 035 $a(EXLCZ)995400000000045281 100 $a20202203d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances and Novel Treatment Options in Metastatic Melanoma 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (528 p.) 311 08$a3-0365-3304-4 311 08$a3-0365-3303-6 330 $aThe book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field. 606 $aMedicine and Nursing$2bicssc 610 $aABT-737 610 $aacetazolamide 610 $aacetylcholine 610 $aadjuvant therapy 610 $aamoeboid motility 610 $aangiogenesis 610 $aapoptosis 610 $aarthralgia 610 $aBcl-2 family 610 $aBCL2L10 610 $abiomarkers 610 $aBRAF 610 $aBRAF inhibitor 610 $aBRAF inhibitors 610 $aBRAF-mutant melanoma 610 $acancer 610 $acancer associated fibroblast 610 $acancer stem cells 610 $acarbonic anhydrase 610 $acell therapy 610 $acheckpoint inhibitor 610 $acholinergic system 610 $acombined therapy 610 $actDNA 610 $aCXCL10 610 $acyclopamine 610 $acytokines 610 $acytotoxicity 610 $adiagnosis 610 $aDOCK4 610 $adrug resistance 610 $aessential oils 610 $aexosomes 610 $aextracellular vesicles 610 $aFAK 610 $ahedgehog 610 $aHIPPO 610 $aHuR 610 $aimmunity 610 $aimmunotherapy 610 $ainterferon 610 $ainvasion 610 $aipilimumab 610 $alactate dehydrogenase 610 $alipid metabolism 610 $aliquid biopsy 610 $aliver-directed-therapies 610 $amachine learning 610 $aMANS peptide 610 $aMARCKS 610 $amechanism of action 610 $amelanoma 610 $amelanoma immune infiltrate 610 $amelanoma markers 610 $amelanoma metastasis 610 $amelanoma PDX 610 $amelanomagenesis 610 $ametalloproteinases 610 $ametastases 610 $ametastasis 610 $ametastatic dormancy 610 $ametastatic therapy 610 $ametastatic uveal melanoma (mUM) 610 $amicroenvironment 610 $amicroRNAs 610 $aMITF 610 $aML258 610 $amotility 610 $amucosal melanoma 610 $amuscarinic receptors 610 $an/a 610 $ananoparticles 610 $anicotinic receptors 610 $anivolumab 610 $aOXPHOS 610 $apatient stratification 610 $aPD-1 610 $apembrolizumab 610 $aphosphorylation 610 $aplasmacytoid dendritic cells 610 $aprediction 610 $aprincipal component analysis 610 $aprognosis 610 $aprognostication 610 $aprotein tyrosine phosphatase 610 $aPTPs inhibitors 610 $aRac1 610 $aradiotherapy 610 $aresistance 610 $arheumatoid arthritis 610 $asex-hormones 610 $asex/gender 610 $aShcD adaptor protein 610 $asiRNA 610 $aslow cycling phenotype 610 $asmall molecules 610 $aSOCE 610 $aSTAT3 610 $aSupport Vector Machine 610 $asurvival 610 $atarget therapy 610 $atargeted therapy 610 $atargeted-therapy 610 $atherapeutic resistance 610 $atherapy 610 $aTLR 610 $aTPC2 610 $atumor microenvironment 610 $atumour microenvironment 610 $auveal melanoma (UM) 610 $aWNT5A 615 7$aMedicine and Nursing 700 $aFacchiano$b Antonio$4edt$01304468 702 $aDel Bufalo$b Donatella$4edt 702 $aCare?$b Alessandra$4edt 702 $aFacchiano$b Antonio$4oth 702 $aDel Bufalo$b Donatella$4oth 702 $aCare?$b Alessandra$4oth 906 $aBOOK 912 $a9910557612103321 996 $aAdvances and Novel Treatment Options in Metastatic Melanoma$93027450 997 $aUNINA